Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• Lung Cancer Screening Eligibility Assessment: Complete Statistical AnalysisIndependent statistical analysis of Lung Cancer Screening Eligibility Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06133816).Phase NAResults postedn = 6,125NCT06133816
• Lung Health StudyIndependent statistical analysis of the Lung Health Study (NCT06290869), a randomized phase 3 study evaluating phone-based tobacco treatment, nicotine replacement, stepped care, and e-referral to the tobacco quitline for smoking cessation.Phase 3n = 1,188NCT06290869
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence…Phase 2/3Results postedn = 53NCT02785939
• LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780268).Phase 3Results postedn = 314NCT05780268
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 153NCT03840902
• MA181Independent statistical analysis of Assessing Choice in the Employer Setting (ACES) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00808808).Phase NAResults postedn = 4,411NCT00808808
• Macrophage Phagocytosis in COPD: Complete Statistical AnalysisIndependent statistical analysis of Macrophage Phagocytosis in COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00298389).Phase NAResults postedn = 56NCT00298389
• MADIndependent statistical analysis of Mandibular Advancement Device and Changes in Nocturia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05562388).Phase NAResults postedn = 11NCT05562388
• MAGE-A4ᶜ¹º³²T for Multi-Tumor: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A4ᶜ¹º³²T for Multi-Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03132922).Phase 1Results postedn = 71NCT03132922
• MAHALEIndependent statistical analysis of Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 100NCT05006573
• Malignant Pleural Effusion With ZD6474: Complete Statistical AnalysisIndependent statistical analysis of Malignant Pleural Effusion With ZD6474: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00402896).Phase 2Results postedn = 28NCT00402896
• MANDALAA detailed statistical analysis of the phase 3 MANDALA trial of budesonide/albuterol metered-dose inhalers versus albuterol in adults and children 4 years of age or older with asthma, including time-to-event, rate, binary,…Phase 3Results postedn = 3,132NCT03769090
• Manual Ventilation Efficacy With MVG Device: Complete Statistical AnalysisIndependent statistical analysis of Manual Ventilation Efficacy With MVG Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05059366).Phase NAResults postedn = 32NCT05059366
• Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE: Complete Statistical AnalysisIndependent statistical analysis of Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 310NCT04688320
• Mast Cell Activation Test in Allergic Disease: Complete Statistical AnalysisIndependent statistical analysis of Mast Cell Activation Test in Allergic Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03406325).Phase NAResults postedn = 19NCT03406325
• MasterKey-01Independent statistical analysis of A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 91NCT04209465
• MATINEEAn independent statistical analysis of the phase 3 MATINEE trial of mepolizumab 100 mg versus placebo in COPD with frequent exacerbations and raised eosinophil levels, covering the negative binomial exacerbation-rate analysis, Cox…Phase 3Results postedn = 806NCT04133909
• Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation: Complete Statistical AnalysisIndependent statistical analysis of Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 40NCT04399980
• MDX1106-01Independent statistical analysis of A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 39NCT00441337
• MeCISIndependent statistical analysis of MethaCholine Bronchoprovocation Study (MeCIS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705341).Phase 4Results postedn = 219NCT00705341
• MELODY-1Independent statistical analysis of MELODY-1, a randomized phase 2 study of macitentan versus placebo in subjects with combined pre- and post-capillary pulmonary hypertension due to left ventricular dysfunction, including its primary endpoint,…Phase 2Results postedn = 63NCT02070991
• MELTEMIIndependent statistical analysis of A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 447NCT02808819
• MERMAID-1Independent statistical analysis of Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate…Phase 3Results postedn = 89NCT04385368
• MetaNeb® Chest X-ray Study: Complete Statistical AnalysisIndependent statistical analysis of MetaNeb® Chest X-ray Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02871258).Phase NAResults postedn = 8NCT02871258
• Metformin in Non Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Metformin in Non Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02285855).Phase 2Results postedn = 27NCT02285855
• METRASIndependent statistical analysis of Metabolites of Tramadol in the Postoperative Surgical Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04004481).Phase NAResults postedn = 50NCT04004481
• METROIndependent statistical analysis of Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 14NCT02019979
• MGC018 With or Without MGA012 in Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of MGC018 With or Without MGA012 in Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03729596).Phase 1/2Results postedn = 143NCT03729596
• Mindfulness Therapy for Individuals With Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Mindfulness Therapy for Individuals With Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01565980).Phase NAResults postedn = 40NCT01565980
• Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis: Complete Statistical AnalysisIndependent statistical analysis of Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04731129).Phase NAResults postedn = 59NCT04731129
• Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial: Complete Statistical AnalysisIndependent statistical analysis of Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03508830).Phase 3Results postedn = 91NCT03508830
• MMPHIndependent statistical analysis of Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 15NCT05387889
• Mobile Health and COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Mobile Health and COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05074693).Phase NAResults postedn = 822NCT05074693
• ModOSAIndependent statistical analysis of Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 105NCT02494102
• Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549328).Phase 2Results postedn = 14NCT00549328
• Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367): Complete Statistical AnalysisIndependent statistical analysis of Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00442559).Phase 4Results postedn = 191NCT00442559
• Montelukast in Perennial Allergic Rhinitis – 2001-2002 Study (0476-246): Complete Statistical AnalysisIndependent statistical analysis of Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00974571).Phase 3Results postedn = 1,365NCT00974571
• MORPHEOIndependent statistical analysis of A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma: primary endpoint results, effect estimate…Phase 4Results postedn = 202NCT04502862
• Morpheus LungIndependent statistical analysis of A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer): primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 314NCT03337698
• MOVEIndependent statistical analysis of Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels…Phase 3Results postedn = 194NCT01996319
• MOVe-AHEADIndependent statistical analysis of the phase 3 MOVe-AHEAD trial of molnupiravir for prevention of Coronavirus Disease (COVID-19) in adults, including endpoint definitions, score-based confidence intervals, reported results, safety, and statistical interpretation.Phase 3Results postedn = 2,441NCT04939428
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180634).Phase 3Results postedn = 330NCT01180634
• MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780463).Phase 3Results postedn = 485NCT05780463
• Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube: Complete Statistical AnalysisIndependent statistical analysis of Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 71NCT02787681
• Myocardial Injury and Quality of Life After COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Myocardial Injury and Quality of Life After COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04794062).Phase NAResults postedn = 119NCT04794062
• Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 37NCT00833261
• NARLALIndependent statistical analysis of Navelbine And Radiotherapy in Locally Advanced Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00887783).Phase 2Results postedn = 117NCT00887783
• Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.: Complete Statistical AnalysisIndependent statistical analysis of Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 40NCT01703663
• Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation: Complete Statistical AnalysisIndependent statistical analysis of Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00415493).Phase NAResults postedn = 24NCT00415493
• National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC: Complete Statistical AnalysisIndependent statistical analysis of National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 76NCT03982459

← All therapeutic areas